Our analysis of changes in individual tumor area revealed a reduction in tumor size in the majority (4/7; 57%) of a-TEA-LS + aPD-L1-treated mice as compared to only 0/7 (0%), 0/7 (0%), and 1/7 (14%) of IgG, a-TEA-LS, and a-PD-L1-treated control cohorts, respectively (Figure 2C). The gene discussed is CD274; the disease is neoplasm.